Lonquex
lipegfilgrastim
Table of contents
Overview
Lonquex is a medicine that contains the active substance lipegfilgrastim. It is used to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients with cancer aged 2 years and older receiving cytotoxic chemotherapy.
Cytotoxic chemotherapy (medicines that kill fast growing cells) commonly causes neutropenia because as well as killing cancer cells, it also kills other fast-growing cells such as neutrophils, leaving the patient at risk of infections.
Lonquex is not used in patients receiving chemotherapy for chronic myeloid leukaemia (a cancer of the white blood cells) and myelodysplastic syndromes (a disease that can develop into a leukaemia).
-
List item
Lonquex : EPAR - Medicine overview (PDF/154.7 KB)
First published: 02/09/2013
Last updated: 02/08/2022
EMA/648073/2022 -
-
List item
Lonquex : EPAR - Risk-management-plan summary (PDF/242.5 KB)
First published: 19/04/2021
Last updated: 02/08/2022
Authorisation details
Product details | |
---|---|
Name |
Lonquex
|
Agency product number |
EMEA/H/C/002556
|
Active substance |
lipegfilgrastim
|
International non-proprietary name (INN) or common name |
lipegfilgrastim
|
Therapeutic area (MeSH) |
Neutropenia
|
Anatomical therapeutic chemical (ATC) code |
L03AA14
|
Publication details | |
---|---|
Marketing-authorisation holder |
Teva B.V.
|
Revision |
24
|
Date of issue of marketing authorisation valid throughout the European Union |
25/07/2013
|
Contact address |
Swensweg 5 |
Product information
17/10/2022 Lonquex - EMEA/H/C/002556 - IAIN/0075
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunostimulants
-
Colony stimulating factors
Therapeutic indication
Lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).